Tech Company Financing Transactions
Aerovate Therapeutics Funding Round
Sofinnova Ventures, Atlas Venture and Cormorant Asset Management participated in a $72.6 million Series A funding round for Aerovate Therapeutics. The round was announced on 8/7/2020.
Transaction Overview
Company Name
Announced On
8/7/2020
Transaction Type
Venture Equity
Amount
$72,600,000
Round
Series A
Investors
Sofinnova Ventures (Lead Investor) (Maha Katabi)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Berkeley St. 18th Floor
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Website
Email Address
Overview
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's lead program is a potentially disease modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
Hunter Gillies
President
Benjamin Dake
VP - Bus. Development
Ralph Niven
Browse more venture capital transactions:
Prev: 8/7/2020: Dapper Labs venture capital transaction
Next: 8/7/2020: Fractyl Laboratories venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs